Abstract
CONVENTIONAL randomized clinical trials of new treatments usually rely on clinical end points that directly show the effect of the new treatment on outcomes such as quality or length of life. In chronic diseases, like cancer, cardiovascular disease, and human immunodeficiency virus (HIV) infection, standard clinical end points may be either distant in time or rare, and thus require a trial of long duration, large sample size, or both to demonstrate the value of a new treatment. A surrogate marker for that clinical end point would allow more rapid completion of clinical investigations of new therapies. The use of surrogate markers in evaluating effective therapies for HIV infection has drawn considerable attention. See also pp 158 and 161. A perfect surrogate marker for use in the study of a new therapeutic agent must be biologically plausible, measurable in all patients with the disease, predictive of disease progression (ie, worsening with
Keywords
MedicineSurrogate endpointClinical trialHuman immunodeficiency virus (HIV)DiseaseRandomized controlled trialClinical endpointInternal medicineIntensive care medicineOncologyImmunology
Affiliated Institutions
Related Publications
Surrogate Markers in AIDS: Where Are We? Where Are We Going?
Editorials1 April 1992Surrogate Markers in AIDS: Where Are We? Where Are We Going?Stephen W. Lagakos, PhD, Daniel F. Hoth, MDStephen W. Lagakos, PhD, Daniel F. Hoth, MDAuthor, A...
Surrogate End Points in Clinical Trials: Are We Being Misled?
Phase 3 clinical trials, which evaluate the effect that new interventions have on the clinical outcomes of particular relevance to the patient (such as death, loss of vision, or...
Changes in Plasma HIV RNA Levels and CD4+ Lymphocyte Counts Predict Both Response to Antiretroviral Therapy and Therapeutic Failure
An adequate virologic response after initiation of antiretroviral therapy seems to require a decrease in plasma HIV RNA level of at least 0.5 log10 copies/mL that is sustained f...
High Levels of HIV-1 in Plasma During All Stages of Infection Determined By Competitive PCR
Quantitative competitive polymerase chain reaction (QC-PCR) methods were used to quantify virion-associated human immunodeficiency virus type-1 (HIV-1) RNA in plasma from 66 pat...
Meta-analysis for the evaluation of potential surrogate markers
We describe a meta-analysis approach for the evaluation of a potential surrogate marker. Surrogate markers are useful in helping to identify therapeutic mechanisms of action and...
Publication Info
- Year
- 1996
- Type
- article
- Volume
- 276
- Issue
- 2
- Pages
- 159-159
- Citations
- 24
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
24
OpenAlex
Cite This
Lawrence Deyton
(1996).
Importance of Surrogate Markers in Evaluation of Antiviral Therapy for HIV Infection.
JAMA
, 276
(2)
, 159-159.
https://doi.org/10.1001/jama.1996.03540020081034
Identifiers
- DOI
- 10.1001/jama.1996.03540020081034